Your browser doesn't support javascript.
Gastrointestinal Symptoms and Outcomes in Hospitalized Coronavirus Disease 2019 Patients.
Ramachandran, Preethi; Onukogu, Ifeanyichkwu; Ghanta, Snigdha; Gajendran, Mahesh; Perisetti, Abhilash; Goyal, Hemant; Aggarwal, Alok.
  • Ramachandran P; Department Hematology and Oncology, Brookdale University Hospital and Medical Center, Brooklyn, New York, USA.
  • Onukogu I; Department of Medicine, Brookdale University Hospital and Medical Center, Brooklyn, New York, USA.
  • Ghanta S; Department of Medicine, Brookdale University Hospital and Medical Center, Brooklyn, New York, USA.
  • Gajendran M; Department of Medicine, Texas Tech University, Paul L. Foster School of Medicine, El Paso, Texas, USA.
  • Perisetti A; Department of Gastroenterology and Hepatology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
  • Goyal H; Department of Medicine, The Wright Center for Graduate Medical Education, Scranton, Pennsylvania, USA, doc.hemant@yahoo.com.
  • Aggarwal A; Department of Hepatobiliary and Pancreatic Surgery, Brookdale University Hospital and Medical Center, Brooklyn, New York, USA.
Dig Dis ; 38(5): 373-379, 2020.
Article in English | MEDLINE | ID: covidwho-772139
ABSTRACT

INTRODUCTION:

Gastrointestinal (GI) symptoms are increasingly being recognized in coronavirus disease 2019 (COVID-19). It is unclear if the presence of GI symptoms is associated with poor outcomes in COVID-19. We aim to assess if GI symptoms could be used for prognostication in hospitalized patients with COVID-19.

METHODS:

We retrospectively analyzed patients admitted to a tertiary medical center in Brooklyn, NY, from March 18, 2020, to March 31, 2020, with COVID-19. The patients' medical charts were reviewed for the presence of GI symptoms at admission, including nausea, vomiting, diarrhea, and abdominal pain. COVID-19 patients with GI symptoms (cases) were compared with COVID-19 patients without GI symptoms (control).

RESULTS:

A total of 150 hospitalized COVID-19 patients were included, of which 31 (20.6%) patients had at least 1 or more of the GI symptoms (cases). They were compared with the 119 COVID-19 patients without GI symptoms (controls). The average age among cases was 57.6 years (SD 17.2) and control was 63.3 years (SD 14.6). No statistically significant difference was noted in comorbidities and laboratory findings. The primary outcome was mortality, which did not differ between cases and controls (41.9 vs. 37.8%, p = 0.68). No statistically significant differences were noted in secondary outcomes, including the length of stay (LOS, 7.8 vs. 7.9 days, p = 0.87) and need for mechanical ventilation (29 vs. 26.9%, p = 0.82).

DISCUSSION:

In our study, the presence of GI manifestations in COVID-19 at the time of admission was not associated with increased mortality, LOS, or mechanical ventilation.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Coronavirus Infections / Betacoronavirus / Gastrointestinal Diseases Type of study: Diagnostic study / Observational study / Prognostic study Topics: Long Covid Limits: Adult / Aged / Female / Humans / Male / Middle aged Country/Region as subject: North America Language: English Journal: Dig Dis Journal subject: Gastroenterology Year: 2020 Document Type: Article Affiliation country: 000509774

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Coronavirus Infections / Betacoronavirus / Gastrointestinal Diseases Type of study: Diagnostic study / Observational study / Prognostic study Topics: Long Covid Limits: Adult / Aged / Female / Humans / Male / Middle aged Country/Region as subject: North America Language: English Journal: Dig Dis Journal subject: Gastroenterology Year: 2020 Document Type: Article Affiliation country: 000509774